Your browser doesn't support javascript.
loading
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
de Jonge, Maja J A; Steeghs, Neeltje; Lolkema, Martijn P; Hotte, Sebastien J; Hirte, Hal W; van der Biessen, Diane A J; Abdul Razak, Albiruni R; De Vos, Filip Y F L; Verheijen, Remy B; Schnell, David; Pronk, Linda C; Jansen, Monique; Siu, Lillian L.
Afiliação
  • de Jonge MJA; Department of Internal Oncology, Erasmus Medical Centre Cancer Institute, Dr. Molenwaterplein 40, 3015 GD, Rotterdam, The Netherlands. m.dejonge@erasmusmc.nl.
  • Steeghs N; Department of Medical Oncology and Clinical Pharmacology, Netherlands Cancer Institute, Plesmanlaan 12, 11066 CX, Amsterdam, The Netherlands.
  • Lolkema MP; Department of Internal Oncology, Erasmus Medical Centre Cancer Institute, Dr. Molenwaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • Hotte SJ; Department of Medical Oncology, University Medical Center Utrecht, Utrecht Cancer Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
  • Hirte HW; Division of Medical Oncology, Juravinski Cancer Centre, 3rd Floor, 699 Concession Street, Hamilton, ON, L8V 5C2, Canada.
  • van der Biessen DAJ; Division of Medical Oncology, Juravinski Cancer Centre, 3rd Floor, 699 Concession Street, Hamilton, ON, L8V 5C2, Canada.
  • Abdul Razak AR; Department of Internal Oncology, Erasmus Medical Centre Cancer Institute, Dr. Molenwaterplein 40, 3015 GD, Rotterdam, The Netherlands.
  • De Vos FYFL; Division of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Suite 5-718, Toronto, ON, M5G 2M9, Canada.
  • Verheijen RB; Department of Medical Oncology, University Medical Center Utrecht, Utrecht Cancer Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
  • Schnell D; Department of Medical Oncology and Clinical Pharmacology, Netherlands Cancer Institute, Plesmanlaan 12, 11066 CX, Amsterdam, The Netherlands.
  • Pronk LC; Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str 65, 88397, Biberach, Germany.
  • Jansen M; Clinical Development Oncology, Boehringer Ingelheim España S.A., Parque Empresarial Alvento, Via de los Poblados, 1 Planta Baja-Edif. B Ofic. A y C, 28033, Madrid, Spain.
  • Siu LL; Medical Department, Boehringer Ingelheim BV, Comeniusstraat 6, 1817 MS Alkmaar, PO Box 8037, 1802 KA, Aklmaar, The Netherlands.
Target Oncol ; 14(1): 43-55, 2019 02.
Article em En | MEDLINE | ID: mdl-30756308
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Quinase 1 de Adesão Focal / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Target Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda País de publicação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Quinase 1 de Adesão Focal / Neoplasias Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Target Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda País de publicação: França